Dietary Approach Effective for Laryngopharyngeal Reflux

Share this content:
Dietary Approach Effective for Laryngopharyngeal Reflux
Dietary Approach Effective for Laryngopharyngeal Reflux

FRIDAY, Sept. 8, 2017 (HealthDay News) -- A dietary approach and a traditional treatment approach of proton pump inhibition (PPI) and standard reflux precautions are similarly effective for patients with laryngopharyngeal reflux (LPR), according to a study published online Sept. 7 in JAMA Otolaryngology -- Head & Neck Surgery.

Craig H. Zalvan, M.D., from New York Medical College in Valhalla, and colleagues conducted a retrospective medical chart review of two treatment cohorts of patients with LPR. Eighty-five patients with LPR who were treated with PPI and standard reflux precautions (PS) were identified from 2010 to 2012. Ninety-nine patients treated with alkaline water; a 90 percent plant-based, Mediterranean-style diet; and standard reflux precautions (AMS) were identified from 2013 to 2015.

The researchers found that 54.1 and 62.6 percent of PS- and AMS-treated patients achieved a clinically meaningful reduction in the Reflux Symptom Index (RSI) (difference between the groups, 8.05; 95 percent confidence interval, −5.74 to 22.76). The mean reduction in RSI was 27.2 and 39.8 percent in the PS and AMS groups, respectively (difference, 12.1; 95 percent confidence interval, 1.53 to 22.68).

"This study suggests that a plant-based diet and alkaline water should be considered in the treatment of LPR," the authors write. "This approach may effectively improve symptoms and could avoid the costs and side effects of pharmacological intervention as well as afford the additional health benefits associated with a healthy, plant-based diet."

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »